Ichthammol
Showing 26 - 50 of 66
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Los Angeles, California
- +1 more
Aug 19, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +4 more
-
Des Moines, Iowa
- +8 more
Jan 12, 2023
Advanced Malignant Tumor, Fatigue, Metastatic Malignant Tumor Trial in Houston (drug, behavioral, other)
Active, not recruiting
- Advanced Malignant Neoplasm
- +4 more
- Dexamethasone
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Mar 3, 2022
Plasmacytoma, POEMS Syndrome Trial in Rochester (Dexamethasone, Ixazomib Citrate, Lenalidomide)
Active, not recruiting
- Plasmacytoma
- POEMS Syndrome
- Dexamethasone
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
May 26, 2022
Metastatic Malignant Tumor in the Brain, Metastatic Malignant Solid Tumor Trial in Atlanta (drug, procedure, radiation)
Recruiting
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Solid Neoplasm
- Dexamethasone
- +2 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Aug 13, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Chemosensitivity Assay,
Terminated
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
May 6, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 30, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 3, 2022
Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma Trial in Rochester, Nashville (Dexamethasone, Ixazomib Citrate,
Active, not recruiting
- Plasma Cell Leukemia
- +2 more
- Dexamethasone
- +3 more
-
Rochester, Minnesota
- +1 more
May 19, 2022
Recurrent Plasma Cell Myeloma Trial in Columbus (Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis)
Completed
- Recurrent Plasma Cell Myeloma
- Dexamethasone
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jun 10, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Ibrutinib, Laboratory
Suspended
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +5 more
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 22, 2022
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (biological, drug, other)
Recruiting
- Plasma Cell Myeloma
- +2 more
- Belantamab Mafodotin
- +4 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 10, 2022
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis Trial in Houston
Recruiting
- Newly Diagnosed Primary Amyloidosis
- +2 more
- Daratumumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 12, 2021
Dyspnea, Malignant Tumor Trial in Houston (Dexamethasone, Placebo, Questionnaire Administration)
Active, not recruiting
- Dyspnea
- Malignant Neoplasm
- Dexamethasone
- +2 more
-
Houston, Texas
- +2 more
Nov 29, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (Bendamustine Hydrochloride, Carfilzomib,
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bendamustine Hydrochloride
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 7, 2021
Recurrent Primary Amyloidosis Trial in United States (drug, biological, other)
Active, not recruiting
- Recurrent Primary Amyloidosis
- Cyclophosphamide
- +5 more
-
Duarte, California
- +4 more
Mar 10, 2021
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (drug,
Terminated
- Multiple Myeloma-Light Chain Only
- +2 more
- Dexamethasone
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Indianapolis, Rochester, Wauwatosa (Bortezomib,
Withdrawn
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Indianapolis, Indiana
- +2 more
Sep 29, 2020
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma Trial in Seattle
Completed
- DS Stage I Plasma Cell Myeloma
- +3 more
- Clarithromycin
- +2 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center/University of Washington
Oct 29, 2019
Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma Trial in Rochester (biological, drug, other)
Completed
- Indolent Plasma Cell Myeloma
- +2 more
- Anakinra
- +4 more
-
Rochester, MinnesotaMayo Clinic
Mar 13, 2020
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, CNS Lymphoma, Intraocular
Completed
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +5 more
- Dexamethasone
- +3 more
-
Scottsdale, Arizona
- +6 more
Jul 18, 2019
Smoldering Plasma Cell Myeloma Trial in United States (biological, drug, other)
Recruiting
- Smoldering Plasma Cell Myeloma
- Daratumumab
- +4 more
-
Anchorage, Alaska
- +595 more
Dec 7, 2022